VASARI Glioma Features: Insights into Their Impact and Performance.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. Pituitary neuroendocrine tumors: imaging features, clinical relevance, and a proposal for standardized MRI reporting.Neuroradiology · 2026
   Review
2. Assessing inter-rater reliability of MRI features in glioma: a multi-radiologist agreement study.BMC medical imaging · 2025
   Article
3. Characteristics and outcomes of diffuse non-midline gliomas with H3F3A gene mutation in the Kansai Molecular Diagnosis Network for CNS Tumors (Kansai Network): multicenter retrospective cohort study.Acta neuropathologica communications · 2025
   Article
4. Tertiary lymphoid structures in glioblastoma: Association with multiparametric MRI imaging phenotypic features and patient survival.Neuro-oncology advances
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as